New triple therapy aims to protect kidneys in diabetes patients
NCT ID NCT07537088
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a weekly injection called dulaglutide to two standard pills (SGLT-2 inhibitors and finerenone) can better protect the kidneys of Chinese adults with type 2 diabetes and mild-to-moderate chronic kidney disease. About 468 participants will be randomly assigned to either continue their current two-drug regimen or add dulaglutide for 26 weeks. The main goal is to see if the triple therapy reduces protein in the urine, a key sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dulaglutide (a once-weekly injection for diabetes) added to SGLT-2 inhibitors and finerenone (both pills)
- What this could lead to
- If it works, this could point toward a better way to slow kidney damage in people with type 2 diabetes and chronic kidney disease.
- What could go wrong
- This is a phase 4 trial with 468 participants over 26 weeks, so results may not apply to all patients. Adding dulaglutide may increase side effects like nausea or diarrhea without clear kidney benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CKD - CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI-Powered trial asks: does adding a second drug cut heart failure risk?
- Protein clues in kidney disease could predict anemia and heart risks
- Can an Anti-Inflammatory diet tame type 2 diabetes?
- New diabetes combo pill aims to beat single drugs in major trial
- New combo therapy aims to improve diabetes management
- New combo diabetes pill tested in healthy volunteers